NCT04075305 (MOMENTUM) is a clinical trial of Radiation therapy in Oncology, sponsored by UMC Utrecht.

Who is sponsoring NCT04075305?

NCT04075305 is sponsored by UMC Utrecht.

What drugs are being tested in NCT04075305?

Interventions in NCT04075305: Radiation therapy.

What condition does NCT04075305 study?

NCT04075305 studies Oncology, Breast Cancer, Prostate Cancer, Gynecologic Cancer, Brain Tumor, Brain Cancer, Gynecologic Tumor, Prostate Tumor, Prostate Neoplasm, Breast Tumor, Radiation Toxicity, Quality of Life, Rectal Cancer, Rectal Tumor, Rectal Neoplasms, Lung Cancer, Lung Tumor, Lung Neoplasm, Esophageal Cancer, Esophagus Cancer, Esophageal Tumor, Esophageal Neoplasm, Esophagus Tumor, Esophagus Neoplasm, Pancreatic Cancer, Pancreatic Tumor, Pancreatic Neoplasms, Head and Neck Cancer, Head and Neck Neoplasms, Head and Neck Tumor, Tumor, Neoplasms, Bladder Cancer, Bladder Neoplasm, Liver Cancer, Liver Neoplasms, Liver Metastases, Oligometastases.

Is NCT04075305 still recruiting?

NCT04075305 is currently recruiting now. Last updated 5 March 2026.

Last reviewed 2026-03-05 · How we verify

NCT04075305: MOMENTUM

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study

Recruiting now Last updated 5 March 2026

What this trial tests

trial testing Radiation therapy in Oncology in 8,000 participants. Currently enrolling.

Timeline

1 February 2019

Primary endpoint
1 February 2030

1 August 2030

Quick facts

Lead sponsor	UMC Utrecht
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	8,000
Start date	1 February 2019
Primary completion	1 February 2030
Estimated completion	1 August 2030
Sites	18 locations across Denmark, Italy, Netherlands, Belgium, United Kingdom, Germany, Canada, Australia

Drugs / interventions tested

Radiation therapy — full drug profile →

Conditions studied

Oncology — all drugs for Oncology →
Breast Cancer — all drugs for Breast Cancer →
Prostate Cancer — all drugs for Prostate Cancer →
Gynecologic Cancer — all drugs for Gynecologic Cancer →

Sponsor

UMC Utrecht — full company profile →

Who can join

18 and older, any sex, with Oncology or Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The Multi-OutcoMe EvaluatioN of radiation Therapy Using the Unity MR-Linac Study (MOMENTUM) is a multi-institutional, international registry facilitating evidenced based implementation of the Unity MR-Linac technology and further technical development of the MR-Linac system with the ultimate purpose to improve patients' survival, local, and regional tumor control and quality of life.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

The MOMENTUM Study: An International Registry for the Evidence-Based Introduction of MR-Guided Adaptive Therapy.
de Mol van Otterloo SR, Christodouleas JP, Blezer ELA, Akhiat H, et al · · 2020 · cited 115× · PMID 33014774 · DOI 10.3389/fonc.2020.01328
Magnetic resonance linear accelerator technology and adaptive radiation therapy: An overview for clinicians.
Hall WA, Paulson E, Li XA, Erickson B, et al · · 2022 · cited 76× · PMID 34792808 · DOI 10.3322/caac.21707
Initial Feasibility and Clinical Implementation of Daily MR-Guided Adaptive Head and Neck Cancer Radiation Therapy on a 1.5T MR-Linac System: Prospective R-IDEAL 2a/2b Systematic Clinical Evaluation of Technical Innovation.
McDonald BA, Vedam S, Yang J, Wang J, et al · · 2021 · cited 63× · PMID 33340604 · DOI 10.1016/j.ijrobp.2020.12.015
MR-Guided Radiotherapy for Prostate Cancer.
Tocco BR, Kishan AU, Ma TM, Kerkmeijer LGW, et al · · 2020 · cited 62× · PMID 33363041 · DOI 10.3389/fonc.2020.616291
Initial clinical experience of Stereotactic Body Radiation Therapy (SBRT) for liver metastases, primary liver malignancy, and pancreatic cancer with 4D-MRI based online adaptation and real-time MRI monitoring using a 1.5 Tesla MR-Linac.
Hall WA, Straza MW, Chen X, Mickevicius N, et al · · 2020 · cited 46× · PMID 32764748 · DOI 10.1371/journal.pone.0236570
Patterns of Care, Tolerability, and Safety of the First Cohort of Patients Treated on a Novel High-Field MR-Linac Within the MOMENTUM Study: Initial Results From a Prospective Multi-Institutional Registry.
de Mol van Otterloo SR, Christodouleas JP, Blezer ELA, Akhiat H, et al · · 2021 · cited 43× · PMID 34265394 · DOI 10.1016/j.ijrobp.2021.07.003
Lutetium-177-PSMA-I&T as metastases directed therapy in oligometastatic hormone sensitive prostate cancer, a randomized controlled trial.
Privé BM, Janssen MJR, van Oort IM, Muselaers CHJ, et al · · 2020 · cited 33× · PMID 32928177 · DOI 10.1186/s12885-020-07386-z
Prospective evaluation of in vivo and phantom repeatability and reproducibility of diffusion-weighted MRI sequences on 1.5 T MRI-linear accelerator (MR-Linac) and MR simulator devices for head and neck cancers.
McDonald BA, Salzillo T, Mulder S, Ahmed S, et al · · 2023 · cited 30× · PMID 37211282 · DOI 10.1016/j.radonc.2023.109717

Verify or expand the search:

Other trials of Radiation therapy

Trials testing the same drug.

NCT06990061 — Radiotherapy for BCG-unresponsive Non-muscle-invasive Carcinoma in Situ (CIS) Bladder Cancer: an Open-label, Single-arm, · NA · not yet recruiting
NCT06831526 — Neoadjuvant Chemoradiotherapy With or Without Concurrent Azeliragon in Patients With Newly Diagnosed Glioblastoma · EARLY_PHASE1 · recruiting
NCT05608369 — Vorinostat in Combination With Chemoradiation in Locally Advanced HPV Negative HNSCC · Phase 2 · withdrawn
NCT06702033 — The Minimalist Trial-2 · Phase 2 · recruiting
NCT06583070 — SABR Combined With Targeted Therapy and Anti-PD-1 for Recurrent or Metastatic Renal Cancer · recruiting

Other recruiting trials for Oncology

Currently open trials in the same condition.

NCT07341464 — Acceptability and Tolerance Study of Bolus Tube Feed With Food Blends · NA · recruiting
NCT07262632 — Developing a Multimodal Cancer Pain Database to Support AI-Based Automatic Pain Assessment · recruiting
NCT06868524 — Leading Healthy Eating and Activity Promotion Program · NA · recruiting
NCT06959810 — Impact of Adapted Aesthetic Onco in Patients With Upper Aerodigestive Tract Cancer During Their Management · NA · recruiting
NCT06950073 — Curatively Intended Thoracic Reirradiation · recruiting

Other UMC Utrecht trials

Trials by the same sponsor.

NCT07512336 — A Randomized Intra-Patient Controlled Trial of MagnetOs™ Putty vs Autograft in Instrumented Posterolateral Spinal Fusion · NA · not yet recruiting
NCT07485985 — Coronary Sinus Reducer Therapy for Persisting Angina · NA · not yet recruiting
NCT07449052 — Comprehensive Invasive Physiological Evaluation of Obstructive Coronary Artery Disease · NA · not yet recruiting
NCT05375708 — Systemic Therapy in Combination with Stereotactic Radiotherapy in Patients with Metastatic Colorectal Cancer Up to 10 Me · Phase 2 · suspended
NCT06898541 — Coronary Sinus Reducer in Coronary Microvascular Disease · NA · enrolling by invitation

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04075305 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by UMC Utrecht
Last refreshed: 5 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04075305.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing